Tutores

Campos de conocimiento

LINEAS DE INVESTIGACIÓN:

1. Mecanismos de evasión de las células tumorales a la respuesta inmune del huésped. 2. Estudio de los “checkpoints inmunes” en pacientes con cáncer pulmonar. 3. Resistencia primaria y adquirida a la terapia blanco y quimioterapia en cáncer pulmonar. 4. Compuestos naturales con actividad antitumoral.

1. Marroquín-Muciño M, Benito-Lopez JJ, Perez-Medina M, Aguilar-Cazares D, Galicia-Velasco M, Chavez-Dominguez R, Meza-Toledo SE, Meneses-Flores M, Camarena A, Lopez-Gonzalez JS. SOCS1 inhibits IL-6-induced CD155 overexpression in lung adenocarcinoma. Int. J. Mol. Sci. 2024,25, 12141. doi.org/10.3390/ijms252212141 (IF= 4.9)

2. Meneses-Flores M, Lopez-Gonzalez JS, Becceril E, Santos-Torres S, Bolaños-Morales F, Aguilar-Cazares D, Luna-Rivero C. COVID-19-induced changes in the fibrin network of pulmonary and renal microthrombi. International Journal of Coronaviruses. 5. 18-29. 10.14302/issn.2692-1537.ijcv-24-5218. ()

3. Perez-Medina M, Lopez-Gonzalez JS, Benito-Lopez JJ, Ávila-Ríos S, Soto-Nava M, Matias-Florentino M, Méndez-Tenorio A, Galicia-Velasco M, Chavez-Dominguez R, Meza-Toledo SE, Aguilar-Cazares D. Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Targeted Therapy in Lung Adenocarcinoma Cell Lines. Cancers (Basel). 2024 Jul 8;16(13):2490. doi: 10.3390/cancers16132490. (IF= 4.5)

4. Chavez-Dominguez R, Aguilar-Cazares D, Perez-Medina M, Avila-Rios S, Soto-Nava M, Mendez-Tenorio A, Islas-Vazquez L, Benito-Lopez JJ, Galicia-Velasco M, Lopez-Gonzalez JS. Transcriptional signature of early cisplatin drug-tolerant persister cells in lung adenocarcinoma. Front Oncol. 2023 Oct 17;13:1208403. doi: 10.3389/fonc.2023.1208403. (IF= 3.5)

5. Benito-Lopez JJ, Marroquin-Muciño M, Perez-Medina M, Chavez-Dominguez R, Aguilar-Cazares D, Galicia-Velasco M, Lopez-Gonzalez JS. Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment. Front Oncol. 2023 Jan 12;12:1101503. doi: 10.3389/fonc.2022.1101503. (IF= 3.5)

6. Aguilar-Cazares D, Chavez-Dominguez R, Marroquin-Muciño M, Perez-Medina M, Benito-Lopez JJ, Camarena A, Rumbo-Nava U, Lopez-Gonzalez JS. The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. Front Endocrinol (Lausanne). 2022 Aug 22;13:929572. doi: 10.3389/fendo.2022.929572. (IF= 3.9)

7. Bautista-Becerril B, Pérez-Dimas G, Sommerhalder-Nava PC, Hanono A, Martínez-Cisneros JA, Zarate-Maldonado B, Muñoz-Soria E, Aquino-Gálvez A, Castillejos-López M, Juárez-Cisneros A, Lopez-Gonzalez JS, Camarena A. miRNAs, from Evolutionary Junk to Possible Prognostic Markers and Therapeutic Targets in COVID-19. Viruses. 2021 Dec 27;14(1):41. doi: 10.3390/v14010041. (IF= 3.8)

8. Chavez-Dominguez RL, Perez-Medina MA, Lopez-Gonzalez JS, Galicia-Velasco M, Matias-Florentino M, Avila-Rios S, Rumbo-Nava U, Salgado-Aguayo A, Gonzalez-Gonzalez C, Aguilar-Cazares D. Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines. Front Oncol. 2021 Dec 13;11:750677. doi: 10.3389/fonc.2021.750677. (IF= 3.5)

9. Chavez-Dominguez R, Perez-Medina M, Aguilar-Cazares D, Galicia-Velasco M, Meneses-Flores M, Islas-Vazquez L, Camarena A, Lopez-Gonzalez JS. Old and New Players of Inflammation and Their Relationship With Cancer Development. Front Oncol. 2021 Nov 22;11:722999. doi: 10.3389/fonc.2021.722999. (IF= 3.5)

10. Islas-Vazquez L, Aguilar-Cazares D, Galicia-Velasco M, Rumbo-Nava U, Meneses-Flores M, Luna-Rivero C, Lopez-Gonzalez JS. IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma. Biology (Basel). 2020 Nov 5;9(11):376. doi: 10.3390/biology9110376. (IF= 3.6)

11. Hernández de la Cruz ON, López-González JS, García-Vázquez R, Salinas-Vera YM, Muñiz-Lino MA, Aguilar-Cazares D, López-Camarillo C, Carlos-Reyes Á. Regulation Networks Driving Vasculogenic Mimicry in Solid Tumors. Front Oncol. 2020 Jan 14;9:1419. doi: 10.3389/fonc.2019.01419. (IF= 3.5)